2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2026

Calcium Crystal-Mediated Netosis in Juvenile Dermatomyositis and Anti-RNP+ Overlap Syndrome with Skin Involvement
Abstract Number: 2027

Whole Exome Trio Sequencing Implicates DOCK2 in Juvenile Idiopathic Arthritis
Abstract Number: 2028

Microwave and Magnetic (M2) Myocardial Proteomics in the Mouse Model of Kawasaki Disease Demonstrates Normalization of the Proteome after Interleukin-1 Inhibition, Potential Novel Biomarkers, and Suggests New Insights into Mechanism of Disease
Abstract Number: 2029

Extended Phenotypic Immunome Characterization (EPIC): A Web-Based Immune Reference Atlas
Abstract Number: 2030

Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension
Abstract Number: 2031

Dysregulated NK Cell PLC
Abstract Number: 2032

Effector T Helper Cell Differentiation and Cytokine Secretion Are Increased in Young Children with Juvenile Idiopathic Arthritis
Abstract Number: 2033

Multiparameter Mass Cytometry By Time-of-Flight Spectrometry (CyTOF) Phenotyping in Pediatric Localized Scleroderma
Abstract Number: 2034

Increased Invasive Capacity and Metabolic Activity in Synovial Fibroblasts from Children with Downs Arthropathy Compared to Juvenile Idiopathic Arthritis
Abstract Number: 2035

Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Abstract Number: 2036

Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2037

CTLA4 Signaling Down-Regulates Fcγ Receptor I Expression on Circulating Monocytes: A Potential Mechanism of Action of Abatacept for RA
Abstract Number: 2038

Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
Abstract Number: 2039

A Survey of Blood and Synovial Tissue Myeloid Cells in RA Patients By Transcriptional Profiling
Abstract Number: 2040

Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].